Slingshot Insights | Sprb Overview

SPRB Overview

Upcoming Projects (SPRB)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (SPRB)

Comparing Neurocrine Biosciences pediatric study results of Crinecerfont in Children and Adolescents with Spruce Biosciences Tildacerfont CAHptain-205 study and dose finding presentation at the Pediatric Endocrine Society (PES) 2024
Tickers: SPRB, NBIX
Executed On: Jun 12, 2024 at 05:00 PM EDT
Discussing CAH (Congenital Adrenal Hyperplasia) and therapies in development, including crinecerfont and tildacerfont
Tickers: SPRB, NBIX
Executed On: Feb 13, 2024 at 04:00 PM EST
A Second Take: Digging into the Phase 2 Data on Spruce Bio's tildacerfont in treating Congenital Adrenal Hyperplasia (CAH)
Ticker: SPRB
Executed On: Mar 13, 2023 at 12:30 PM EDT
A Third View - Digging into the Phase 2 Data on Spruce Bio's tildacerfont in treating Congenital Adrenal Hyperplasia (CAH)
Ticker: SPRB
Executed On: Mar 13, 2023 at 12:00 PM EDT
Digging into the Phase 2 Data on Spruce Bio's tildacerfont in treating Congenital Adrenal Hyperplasia (CAH)
Ticker: SPRB
Executed On: Feb 24, 2023 at 06:00 PM EST

Upcoming & Overdue Catalysts (SPRB)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (SPRB)

Spruce Biosciences (SPRB) to announce Phase 1 and 2 Data of Tildacerfont in Classic Congenital Adrenal Hyperplasia at ENDO March 20, 2021 at 11:00am EST
Ticker: SPRB
Occurred on: Mar 20, 2021

Strategic Initiatives (SPRB)

Don’t see a strategic initiative related to the company you care about? Create your own!